
Mise à jour de mes liens d'intérêt (Mars 2023). Plus de détails sur : transparence.sante.gouv.fr/p… et sur: dpi.sante.gouv.fr/dpi-public…
✓Head of pulmonology unit @pneumo_LS @CHUdeLyon Professor of Pulmonology @UnivLyon1 Scientific head @URCOT_lyon Lung cancer screening and tobacco control addict.

Mise à jour de mes liens d'intérêt (Mars 2023). Plus de détails sur : transparence.sante.gouv.fr/p… et sur: dpi.sante.gouv.fr/dpi-public…

The 🚨 OncoAlert TOP 10 — #WCLC26 🌐 Advanced #NSCLC 🇰🇷 We’re kicking off our OncoAlert TOP 10 for #WCLC26 with a focus on Advanced Non-Small Cell #LungCancer ( #NSCLC )🫁 Leads: Dr. Hidehito Horinouchi 🇯🇵 @HHorinouchi Dr. Uğur Özkerim🇹🇷 @UOzkerim Dr. Oriol Mirallas🇺🇸 @DrMirallas Dr. Gil Morgan 🇺🇸 @WeOncologists Senior Faculty: Dr. Charu Agarwal🇺🇸 @CharuAggarwalMD Dr. Stephen Liu🇺🇸 @StephenVLiu Dr. Gilberto Lopes🇺🇸 @GlopesMd Dr. Sanjay Popat🇬🇧 @DrSanjayPopat Dr. Solange Peters 🇨🇭 @peters_solange Dr. Christine Lovly 🇺🇸 @christine_lovly Our process is simple: our leads identify their picks for the Top 10 studies in each tumor category, which are then sent to our senior OncoAlert Faculty for voting through a Delphi process. These are the studies generating the most interest across perioperative treatment, targeted therapy, immunotherapy, and surgical management of resectable and locally advanced NSCLC. 🔥 THE TOP 10 — Advanced NSCLC 🥇 PL02.03 – Tam-Peli, an Anti-B7-H3 Antibody-Drug Conjugate, Versus Topotecan in Relapsed SCLC: A Randomized, Open-Label, Phase 3 Study (TAISHAN-302) 🥈PL02.04 – Risvutatug Rezetecan (a B7-H3-Directed ADC) Versus Topotecan in Relapsed SCLC: Primary Results of Phase 3 ARTEMIS-008 🥉OA05.01 – Tarlatamab Extended-Interval Dosing Regimens in Patients With SCLC: The Randomized Phase 2 DeLLphi-309 Study OA14.02 – Pumitamig (PD-L1 x VEGF-A bsAb) + Elfetabart Drozuntecan (Elfe-D, B7H3 ADC) in Patients with Advanced/Metastatic Lung Cancer (NSCLC or SCLC) MO15.07 – Subcutaneous (SC) Tarlatamab in Patients W/ Extensive-Stage Small Cell Lung Cancer (ES-SCLC): DeLLphi-308 Ph 1B Study OA05.02 – Phase 1 Study of LB2102, a dnTGFBR2-armored DLL3-targeted Autologous CAR-T Cell Therapy, in Subjects With Relapsed or Refractory SCLC or LCNEC MO15.04 – First-Line YL201 Plus Serplulimab in ES-SCLC and Advanced NSCLC: Phase 1 Results of a B7-H3-Directed Combination Strategy MO15.02 – A Phase 2 Trial of QLC5508 (MHB088C) Plus QL1706 or QL2107 as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer MO15.05 – Expression and Prognostic Impact of B7-H3 in Patients With Extensive-Stage Small-Cell Lung Cancer @ChristianRolfo @NarjustFlorezMD @JackWestMD @bmassutis @Tony_Calles @s_couraud @marinagarassino @UmbertoMalapel1 @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @LeciaSequist @jillfeldman4 @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @DrJNaidoo @caliraf @MartinReck2 @Latinamd @JulienMazieres @TerriConneran @BRicciutiMD @MarioBalsaMD @realbowtiedoc @FernandoOnco @ElisaAgostinett @to_be_elizabeth @p_ciracimd @AmandaNizamMD @scocmem @DrVilmaPBarcia @DraMartinezLago @nataliagandur @GIMedOnc @DaisukeKotani #OncoAlert #WCLC26 #LungCancer #NSCLC #LungCancerResearch #ThoracicOncology #C

The 🚨 OncoAlert TOP 10 — #WCLC26 🌐 #NSCLC 🇰🇷 We’re kicking off our OncoAlert TOP 10 for #WCLC26 with a focus on Early Non-Small Cell #LungCancer ( #NSCLC )🫁 Leads: Dr. Hidehito Horinouchi 🇯🇵 @HHorinouchi Dr. Uğur Özkerim🇹🇷 @UOzkerim Dr. Oriol Mirallas🇺🇸 @DrMirallas Dr. Gil Morgan 🇺🇸 @WeOncologists Senior Faculty: Dr. Charu Agarwal🇺🇸 @CharuAggarwalMD Dr. Stephen Liu🇺🇸 @StephenVLiu Dr. Gilberto Lopes🇺🇸 @GlopesMd Dr. Sanjay Popat🇬🇧 @DrSanjayPopat Dr. Solange Peters 🇨🇭 @peters_solange Dr. Christine Lovly 🇺🇸 @christine_lovly Our process is simple: our leads identify their picks for the Top 10 studies in each tumor category, which are then sent to our senior OncoAlert Faculty for voting through a Delphi process. These are the studies generating the most interest across perioperative treatment, targeted therapy, immunotherapy, and surgical management of resectable and locally advanced NSCLC. 🔥 THE TOP 10 — EARLY NSCLC 🥇 1. PL03.01 Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: ADAURA Exploratory 8-year Overall Survival Landmark Update 🥈 2. OA04.02 Neoadjuvant Durvalumab + Chemotherapy for Resectable/Borderline Resectable Stage IIB-IIIB NSCLC: MDT-BRIDGE Primary Analysis 🥉 3. OA04.03 Final Analysis of Phase 3 IMpower030: Perioperative Atezolizumab + Chemotherapy in Resectable Stage II-IIIB NSCLC 4. OA04.04 Neoadjuvant Divarasib in Resectable KRAS G12C+ NSCLC: Updated NAUTIKA1 Data 5. MO06.01 NAUTIKA1: Neoadjuvant Alectinib in Resectable ALK+ NSCLC 6. OA09.03 Phase 2 JS207 (PD-1/VEGF bispecific) + chemotherapy in Unresectable Stage III NSCLC 7. OA08.01 Wedge Resection vs. Segmentectomy for GGO-Dominant cT1a-bN0M0 NSCLC 8. OA09.02 ASTRES: Phase 2 Atezolizumab in Locally Advanced, Unresectable Stage III NSCLC 9. MO06.07 DUMAS: Neoadjuvant Immunotherapy for Pancoast Tumors 10. OA04.01 Phase 3 Adjuvant Gefitinib + Chemotherapy vs Chemotherapy in EGFR-Mutant NSCLC Pinging OncoAlert Faculty @ChristianRolfo @NarjustFlorezMD @JackWestMD @bmassutis @Tony_Calles @s_couraud @marinagarassino @UmbertoMalapel1 @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @LeciaSequist @jillfeldman4 @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @DrJNaidoo @caliraf @MartinReck2 @Latinamd @JulienMazieres @TerriConneran @BRicciutiMD @MarioBalsaMD @realbowtiedoc @FernandoOnco @ElisaAgostinett @to_be_elizabeth @p_ciracimd @AmandaNizamMD @scocmem @DrVilmaPBarcia @DraMartinezLago @nataliagandur @GIMedOnc @DaisukeKotani 👀 What stands out? The early-stage NSCLC landscape continues to move rapidly toward personalized perioperative therapy, with major interest in EGFR, ALK and KRAS-directed strategies, alongside immunotherapy and surgical optimization. The ADAURA 8-year update takes the #1 spot, tied on votes with the MDT-BRIDGE neoadjuvant durvalumab study. And this is just the beginning… 📲 Follow OncoAlert for more TOP 10 #WCLC26 lists covering the studies our community is watching most closely. Which early NSCLC study are YOU most excited about at #WCLC26? 👇 Let us know in the comments. #OncoAlert #WCLC26 #LungCancer #NSCLC #LungCancerResearch #ThoracicOncology #CancerResearch #Oncology #Immunotherapy #TargetedTherapy

🎯Objectif du programme pilote #IMPULSION : tester, en conditions réelles, un dépistage ciblé pour définir un futur programme organisé national. Financé par @Institut_cancer à hauteur de 6 M€, piloté par les Pr @revelmp (@APHP) et @s_couraud (@CHUdeLyon)


Je déclare ouverte la saison des "vous avez pas mis la bonne date sur le bon de transport" .



Magnifique collaboration interdisciplinaire avec l'équipe du @map_monaco et du @LAAB_Labo à l'initiative de @doctroptard pour amener le scanner au plus près de patients très très âgés... Une expérience enrichissante à reproduire !

... C'était pas naïf, c'était le debut d'une aventure dont on ne savait pas comment elle allait se terminer...


Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020 buff.ly/XW3XLx3 The KBP-2020 study analyzed lung adenocarcinoma outcomes in over 5000 patients treated in nonacademic public hospitals in France and found that median overall survival more than doubled from 8.5 months in 2000 to 20.7 months in 2020. Three-year survival rates improved across all stages, with the most significant gains seen in patients with early-stage disease, favorable performance status, and among those with metastatic disease who received targeted therapy for EGFR/ALK/ROS1 mutations or first-line immunotherapy. These findings highlight the substantial impact of precision medicine and immunotherapy in improving real-world survival outside academic settings. #LungCancer Didier Debieuvre @PneumoCphg Lionel Falchero @FalcheroLionel @s_couraud @ChristianRolfo @GlopesMd @NarjustFlorezMD @StephenVLiu @bmassutis @Tony_Calles @s_couraud @marinagarassino @peters_solange @UmbertoMalapel1 @g_mountzios @CharuAggarwalMD @christine_lovly @barlesi @jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat@JordiRemon @DrJNaidoo @Latinamd @JulienMazieres @TerriConneran #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua

Sidérant @TCL_SYTRAL... -incapables de faire rouler le métro B plus d'une semaine consécutive; -incapables d'informer convenablement les voyageurs. Une nécessaire évaluation du service rendu par cette régie devrait être à l'ordre du jour de la prochaine mandature.

Deeply desserved David ! So great to work again with you !


Parfaitement vrai ! Moi j'ai essayé 3 fois avant d'y arriver !